This subproject is aimed for continued improvement for safety, efficacy, and in vivo study of lentiviral vectors (LV). We have established a self-inactivating (SIN) LV (pTY), a series of recombinant chimera of murine retrovirus and human immunodeficiency virus type 1 (HIV-1) vectors that contains minimal HIV-1 sequences (less than 500 nt) with deletions of all viral splice sites and the Rev-responsive element (RRE). The SIN vector produced up to 10/7 infectious units per ml of unconcentrated vectors when analyzed by a sensitive Cre/lox recombination assay. Analyses of the SIN LV showed that the 3' polyadenylation processing is compromised due to the large deletion of U3 and U5 sequences. Several strategies will be taken to further increase the efficacy, safety and long term stability of LV. In addition, we have generated novel packing cell lines that employ either the Cre-lox recombination or a Cre-progesterone receptor (PR) fusion system that is inducible by RU486 for a large scale LV production. To study transduction, biodistribution, and host responses in vivo, we will explore a nlCre LV and a sensitive lox/lacZ transgenic mouse model. To achieve these goals, the following four specific aims are proposed:
Aim 1 : Modifications of the polyadenylation signal of SN LV for improved efficacy and safety, and insertion of insulators for improved long term stability;
Aim 2 : Analyses of the roles of HIV-RR3 and packing signals in vector function and further characterization of chimeric MLV/HIV-1 vectors;
Aim 3 : Establishing lentiviral packaging cell lines using the Cre-lox and Cre-PR fusion-RU486 inducible systems;
Aim 4 : Ex vivo and in vivo LV transduction of lox/lacZ transgenic mice and analyses of host responses. The proposed studies will establish improved LV and obtain necessary preclinical data with the help of the Pathology Core for future clinical LV applications. This subproject will share materials, models, and core facility with the three AAV subprojects, and continue to jointly explore innovative therapeutic models in the program research center.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL059412-06
Application #
6663406
Study Section
Project Start
2002-09-30
Project End
2003-08-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2002
Total Cost
$219,976
Indirect Cost
Name
University of Florida
Department
Type
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Smith, Barbara K; Martin, A Daniel; Lawson, Lee Ann et al. (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol 287:216-224
Baligand, Celine; Todd, Adrian G; Lee-McMullen, Brittany et al. (2017) 13C/31P MRS Metabolic Biomarkers of Disease Progression and Response to AAV Delivery of hGAA in a Mouse Model of Pompe Disease. Mol Ther Methods Clin Dev 7:42-49
Doerfler, Phillip A; Todd, Adrian G; Clément, Nathalie et al. (2016) Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Hum Gene Ther 27:43-59
Doerfler, Phillip A; Nayak, Sushrusha; Corti, Manuela et al. (2016) Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev 3:15053
Drouin, Lauren M; Lins, Bridget; Janssen, Maria et al. (2016) Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging. J Virol 90:8542-51
Conlon, Thomas J; Mah, Cathryn S; Pacak, Christina A et al. (2016) Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors. Hum Gene Ther Clin Dev 27:152-159
Corti, Manuela; Smith, Barbara K; Falk, Darin J et al. (2015) Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction. Muscle Nerve 51:877-83
Todd, Adrian G; McElroy, Jessica A; Grange, Robert W et al. (2015) Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Ann Neurol 78:222-34
Falk, Darin J; Todd, Adrian Gary; Lee, Sooyeon et al. (2015) Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet 24:625-36
Gruntman, Alisha M; Flotte, Terence R (2015) Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Hum Gene Ther Methods 26:77-81

Showing the most recent 10 out of 100 publications